J

Joincare Pharmaceutical Group Industry Co Ltd
SSE:600380

Watchlist Manager
Joincare Pharmaceutical Group Industry Co Ltd
SSE:600380
Watchlist
Price: 11.42 CNY 0.26% Market Closed
Market Cap: 21.4B CNY
Have any thoughts about
Joincare Pharmaceutical Group Industry Co Ltd?
Write Note

Joincare Pharmaceutical Group Industry Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Joincare Pharmaceutical Group Industry Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
J
Joincare Pharmaceutical Group Industry Co Ltd
SSE:600380
Total Receivables
ÂĄ5B
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
8%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Receivables
ÂĄ3.3B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Receivables
ÂĄ1.1B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Receivables
ÂĄ7.5B
CAGR 3-Years
-7%
CAGR 5-Years
3%
CAGR 10-Years
10%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Receivables
ÂĄ13.2B
CAGR 3-Years
18%
CAGR 5-Years
13%
CAGR 10-Years
11%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Receivables
ÂĄ172.9m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Joincare Pharmaceutical Group Industry Co Ltd
Glance View

Market Cap
21.4B CNY
Industry
Pharmaceuticals

Joincare Pharmaceutical Group Industry Co. Ltd., a noteworthy player in China's bustling pharmaceutical landscape, emerged as a beacon of innovation and resilience. With its roots stretching back to the mid-1990s, the company has consistently carved out a substantial niche in both the generic and proprietary drug markets. Its ability to synergistically blend cutting-edge research with cost-efficient production has been instrumental in ensuring its position as a formidable competitor. Joincare harnesses a robust pipeline of drugs targeting prevalent chronic diseases, complemented by its investment in high-growth biopharmaceuticals. From research and development to manufacturing and distribution, Joincare manages an integrated pharmaceutical supply chain that not only propels its profitability but also reinforces its mission to enhance public health. The company thrives on a diverse revenue model by leveraging both its proprietary products and a broad array of generic pharmaceuticals. It capitalizes on sustained demand for its products across domestic and international markets, ensuring a steady stream of income. By focusing on quality and affordability, Joincare has successfully navigated the complex regulatory landscape, earning certifications that open doors to global markets. This strategic emphasis on rigorous compliance not only mitigates risks but also builds trust with healthcare professionals and end-users alike. Through these efforts, Joincare continues to fortify its market position, all while contributing to the ever-evolving pharmaceutical industry with a pioneering spirit and an unwavering commitment to improving healthcare accessibility.

Intrinsic Value
18.96 CNY
Undervaluation 40%
Intrinsic Value
Price
J

See Also

What is Joincare Pharmaceutical Group Industry Co Ltd's Total Receivables?
Total Receivables
5B CNY

Based on the financial report for Sep 30, 2024, Joincare Pharmaceutical Group Industry Co Ltd's Total Receivables amounts to 5B CNY.

What is Joincare Pharmaceutical Group Industry Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
8%

Over the last year, the Total Receivables growth was -2%.

Back to Top